Literature DB >> 26651256

Non-invasive screening for colorectal cancer in Asia.

Han-Mo Chiu1, Li-Chun Chang2, Wen-Feng Hsu3, Chu-Kuang Chou4, Ming-Shiang Wu5.   

Abstract

There is an increasing trend of colorectal cancer incidence in Asia and nearly 45% of CRC cases worldwide occur in Asia therefore screening for CRC becomes an urgent task. Stool-based tests, including guaiac fecal occult blood test (gFOBT) and fecal immunochemical test (FIT), can select subjects at risk of significant colorectal neoplasms from the large target population thus are currently the most commonly used non-invasive screening tool in large population screening programs. FIT has the advantage over gFOBT in terms of higher sensitivity for early neoplasms, the ability to provide high-throughput automatic analysis, and better public acceptance thus greater effectiveness on reducing CRC mortality and incidence is expected. Owing to the large target population and constrained endoscopic capacity and manpower, FIT is nowadays the most popular CRC screening test in Asia. Some Asian countries have launched nationwide screening program in the past one or two decades but also encountered some challenges such as low screening participation rate, low verification rate after positive stool tests, low public awareness, and insufficient manpower. In addition, some controversial or potential future research issues are also addressed in this review.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Asia; Colorectal cancer (CRC); Fecal immunochemical test (FIT); Guaiac fecal occult blood test (gFOBT); Screening

Mesh:

Substances:

Year:  2015        PMID: 26651256     DOI: 10.1016/j.bpg.2015.09.015

Source DB:  PubMed          Journal:  Best Pract Res Clin Gastroenterol        ISSN: 1521-6918            Impact factor:   3.043


  8 in total

Review 1.  Colorectal Cancer Screening in Asia.

Authors:  Han-Mo Chiu; Wen-Feng Hsu; Li-Chun Chang; Ming-Hsiang Wu
Journal:  Curr Gastroenterol Rep       Date:  2017-08-10

2.  T7 Endonuclease I-mediated voltammetric detection of KRAS mutation coupled with horseradish peroxidase for signal amplification.

Authors:  Pinky Chowdhury; Byung Seok Cha; Seokjoon Kim; Eun Sung Lee; Taehwi Yoon; Jisu Woo; Ki Soo Park
Journal:  Mikrochim Acta       Date:  2022-01-27       Impact factor: 5.833

3.  Transmissibility of the Campaign for Colorectal Cancer Awareness in Korea Among Twitter Users.

Authors:  Keun Chul Lee; Heung-Kwon Oh; Gibeom Park; SoHyun Park; Bongwon Suh; Woo Kyung Bae; Jin Won Kim; Hyuk Yoon; Myung Jo Kim; Sung-Il Kang; Il Tae Son; Duck-Woo Kim; Sung-Bum Kang
Journal:  Ann Coloproctol       Date:  2016-10-31

4.  Rapid and accurate detection of KRAS mutations in colorectal cancers using the isothermal-based optical sensor for companion diagnostics.

Authors:  Choong Eun Jin; Seung-Seop Yeom; Bonhan Koo; Tae Yoon Lee; Jeong Hoon Lee; Yong Shin; Seok-Byung Lim
Journal:  Oncotarget       Date:  2017-08-08

5.  Health Insurance and Colorectal Cancer Survival in Khon Kaen, Thailand.

Authors:  Surachai Phimha; Supannee Promthet; Krittika Suwanrungruang; Jarin Chindaprasirt; Prachak Bouphan; Chalongpon Santong; Patravoot Vatanasapt
Journal:  Asian Pac J Cancer Prev       Date:  2019-06-01

Review 6.  Current Advances in Chitosan Nanoparticles Based Oral Drug Delivery for Colorectal Cancer Treatment.

Authors:  Hazem Choukaife; Salma Seyam; Batoul Alallam; Abd Almonem Doolaanea; Mulham Alfatama
Journal:  Int J Nanomedicine       Date:  2022-09-07

7.  Perceptions of colorectal cancer screening and recommendation behaviors among physicians in Korea.

Authors:  Hye Young Shin; Mina Suh; Boyoung Park; Jae Kwan Jun; Kui Son Choi
Journal:  BMC Cancer       Date:  2017-12-16       Impact factor: 4.430

8.  Higher satisfaction with an alternative collection device for stool sampling in colorectal cancer screening with fecal immunochemical test: a cross-sectional study.

Authors:  Hye Young Shin; Mina Suh; Kui Son Choi; Sang-Hyun Hwang; Jae Kwan Jun; Dong Soo Han; You Kyoung Lee; Jae Hwan Oh; Chan Wha Lee; Do-Hoon Lee
Journal:  BMC Cancer       Date:  2018-04-02       Impact factor: 4.430

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.